AVITA Medical

The Business

AVITA Medical is built around a single device, RECELL, which turns a small sample of a patient's own skin into a spray-on suspension for treating burns and wounds. It has held FDA approval since 2018 and generates the large majority of revenue, sold into roughly 200 US burn and trauma centres. Two newer products, Cohealyx (a dermal matrix) and PermeaDerm (a synthetic wound covering), are cross-sold into the same hospital relationships without requiring a new sales force. International sales and a US government biodefence contract fill out the remainder.

Recent Performance

The most recent quarter marked a genuine inflection. Net cash use fell from US$9.9 million in the first quarter of 2026 to US$3.2 million in the second, and management raised full-year revenue guidance on the back of it. That improvement has driven renewed market enthusiasm for the breakeven story, but it rests on two quarters of data against a company with no prior history of sustained cost discipline.

Outlook

Revenue growth is set to decelerate over the next several years as the core RECELL franchise matures, off a FY25 base of $71.6 million, with growth partly offset by the ramp of Cohealyx and PermeaDerm. Gross margin is expected to drift only modestly lower as these newer, lower-margin products scale within the mix. The more important development to watch is the path toward positive EBITDA (earnings before interest, tax, depreciation and amortisation): the company is forecast to move from a substantial loss toward its first sustained positive figure within the next few years, the point at which the fixed cost base finally gets covered by gross profit.

Key Risks

A liquidity crisis or covenant breach on the existing debt facility would be severely damaging to equity holders, given the cash buffer covers only a few months at current burn and the debt sits senior to shareholders. A delay in reaching sustained breakeven beyond the current target window would likely force a dilutive capital raise, pushing the timeline further out and adding execution risk on top of financing risk. Existing warrants and options represent a meaningful further dilution risk in any downside scenario where additional capital is required.

What to Watch

The thesis-defining event is the October 2026 quarterly result, which will confirm whether the cash burn improvement is durable or a one-off.

• October 2026 Q3 2026 results — continued low cash burn alongside revenue holding at recent run-rate levels would materially support the breakeven case.
• November 2026 Warrant shareholder vote — failure triggers an event of default on the existing debt facility, a binary and largely unhedgeable risk.

Latest Developments

The second quarter of 2026 delivered the company's strongest quarter to date on both revenue and cash burn, prompting a guidance upgrade. It is the first quarter under new leadership to show clear evidence that the FY2024 cost blowout has been genuinely reversed rather than temporarily paused.

Company Description

AVITA Medical's core product, RECELL, sprays a suspension of a patient's own skin cells onto burns and wounds to accelerate healing, reducing the amount of donor skin needed for grafting. Approved by the FDA since 2018, it is sold into roughly 200 US burn and trauma centres and represents around 92% of group revenue. Cohealyx (a dermal matrix) and PermeaDerm (a synthetic wound covering) were added to address adjacent stages of the wound-healing pathway, sold through the same hospital relationships. A US government biodefence contract and modest international sales round out the revenue base.

Where the Growth Is

Cohealyx and PermeaDerm together contribute around 8% of FY26 revenue, up from a near-zero base a year earlier, and are growing at roughly 40% before tapering to single digits by year eight of the forecast. The appeal is structural rather than cyclical: both products leverage existing burn-centre relationships and sales infrastructure, adding several million dollars of annualised revenue without a proportional increase in selling costs.

Competitive Position

RECELL's FDA approval remains unchallenged eight years after it was granted, with no competitor having filed a rival application in autologous cell suspension therapy. That regulatory barrier, requiring years and tens of millions of dollars to replicate, underpins product-level gross margins of around 86% and gives AVITA effective pricing power within its niche. The advantage is narrow in scope, protecting a single therapeutic category rather than a broad market, and we see it holding for another five to seven years before the risk of a competing filing becomes material. It is a stable position rather than a widening one: the company defends what it has rather than continually extending its lead.

Management & Capital Discipline

FY2024 saw an operating expense blowout that was not matched by revenue growth, followed by an aggressive restructuring under new CEO Cary Vance that cut quarterly opex from around $30 million to $24.6 million. Management's operational disclosures on margins, costs and clinical data have proven largely accurate and verifiable. Forward guidance on the timing of profitability has been far less reliable: FY2025 saw three separate guidance cuts and the departure of the prior CEO. The honest read is that the current team's actions look more credible than its stated timelines.

Financial Position

The balance sheet is weak. AVITA carries US$50 million of debt at 11.5%, sits close to its minimum cash covenant, and has negative shareholder equity. At the current burn rate, existing cash covers roughly five months of operations before the company would need either a revenue inflection or additional financing. This is not a business that can comfortably absorb a demand shock or an unexpected cost overrun.